Mallinckrodt plc / InfaCare Pharmaceutical Corporation

Severe Neonatal Hyperbilirubinemia

Disease Overview

Severe neonatal hyperbilirubinemia is a sharp rise in bilirubin in newborns, especially in infants with hemolysis (e.g., ABO/Rh incompatibility, G6PD deficiency), that, untreated, can cross the blood-brain barrier and cause kernicterus, an irreversible neurologic injury. The standard of care is phototherapy, with exchange transfusion and IVIG reserved for severe cases. Universal pre-discharge bilirubin screening and intensive phototherapy have made kernicterus rare in high-income countries.

Competitive Landscape

At deal close (September 2017), severe neonatal hyperbilirubinemia management was almost entirely device- and procedure-based: intensive phototherapy (LED and fiberoptic blanket systems from GE Healthcare, Natus, Drager and others), exchange transfusion in extreme cases, and IVIG for hemolytic disease per AAP guidelines. There was no FDA-approved pharmacologic agent to prevent the rise of bilirubin. Stannsoporfin's heme oxygenase inhibition mechanism would have been the first drug to reduce bilirubin production at its enzymatic source, positioning Mallinckrodt to define a new pharmacologic category in the NICU/well-newborn-nursery setting. The clinical and commercial rationale was compromised by the FDA Joint Advisory Committee's 21-3 vote in May 2018 against approval, citing insufficient effectiveness evidence, followed by a Complete Response Letter in August 2018. The deal's heavily milestone-weighted structure (only $80M of the $425M paid upfront) limited Mallinckrodt's downside, but the program never reached commercialization. With universal screening already containing severe hyperbilirubinemia incidence, the addressable population was always narrow, and no comparable competing pharmacologic candidate has since advanced.